ReGenerCell™ is an innovative treatment that can be used in conjunction with conventional procedures to trigger healing in chronic wounds.

The technology behind ReGenerCell™ enables a small sample of a patient’s own skin to be used to promote healing in otherwise unresponsive chronic wounds.1,2,3

A small skin sample is first collected from a healthy area of skin. While the clinician prepares the affected area to be treated, the ReGenerCell™ device is used to swiftly prepare a suspension of healthy skin cells from the small skin sample, called Regenerative Epithelial Suspension™, or RES™. RES™, contains all the necessary elements4 for the promotion of healthy skin cell growth and regeneration6,7,8 is easily applied by the clinician to the wound.

ReGenerCell™ has been safely used in thousands of procedures worldwide and offers distinct advantages for treating hard to heal wounds:

HOW IT WORKS

Simple. Safe. Effective.

A simple mechanism supported by robust clinical data, and safely used thousands of times.

Takes just 30 minutes to complete the following simple steps:


1

Take a small skin sample from a patient

2

Process in the ReGenerCell™ device

3

Apply the suspension back to the wound

4

Dress the wound and let healing complete


ADVANTAGES

ReGenerCell® offers distinct advantages for the repair of unresponsive chronic wounds.
Avita’s ReGenerCell® unique proprietary technology enables a clinician to rapidly treat a patient using just a small sample of their own skin.  As well as being fast and simple to use, it is proven to be safe and effective.

  • Well suited for chronic wounds such as foot and leg ulcers
  • Promotes healing in unresponsive wounds1,2,3
  • Reduction in pain following treatment1,3
  • Reduction in exudate for improved quality of life.1

Please enquire on availability in your country.

References
  1. Hayes. P. Harding, K. Johnson, S. McCollum, C. Mercer, K. Russell and Teot, L. The effectiveness of autologous cell suspensions to elicit positive changes in quality of life in patients with venous leg ulcers. EP169, Presented at European Wound Management Association, Bremen.
  2. Chant H, Woodrow T and Manley J. Autologous skin cells: a new technique for skin regeneration in diabetic and vascular ulcers (2013) Journal of wound care Case s Supplement S1 0 vol 2 2 , no 1 0
  3. De Angelis B, Migner A, Lucarini L, Agovino A, CervelliV . The use of a non-cultured autologous cell suspension to repair chronic ulcers. International Wound Journal 2013; doi: 10.1111./iwj. 12047 [Epub]
  4. Wood FM, Giles N, Stevenson A, Rea S, ZFear M. Characterisation of the cell suspension harvested from the dermal epidermal junction using a ReCell® kit. Burns 2012; 38:44-51
  5. Singer AJ, Clark RAF. Cutaneous wound healing. New England Journal of Medicine 1999;341(10):738-746.
  6. Pastar I, Stojadinovic O, Yin NC, Ramirez H, Nusbaum AG, Sawaya A, Patel SB, Khalid L, Isseroff RR, Tomic-Canic M. Epithelialization in wound healing: A comprehensive review. Advances in Wound Care 2014; 3(7):445-464
  7. Dunnill, C. and Georgopoulos, N. Personal communication 2016 University of Huddersfield.
  8. Green H, Rheinwald JG, Sun T. Properties of an epithelial cell type in culture: the epidermal keratinocyte and its dependence on products of the fibroblast. Progress in Clinical and Biological research, 1977; 17:493-500.